Shift your focus from low-value manual processes to understanding and interpreting insights to enhance product safety and improve patient outcomes.

Cognitive Adverse Event Intake and Processing

Pharmacovigilance (PV) organizations face a growing volume of adverse event (AE) cases, but today's manual processes can be time-consuming and costly. Now there's a way to automate AE processing to help reduce costs and uncover more insights that can improve product safety.

With the growing number of AE events reported through traditional sources, PV organizations are struggling to cope while maintaining their focus on safety. These challenges will likely increase as adoption of new technologies (e.g., wearables) and potential new regulatory guidance on non-traditional real-world sources raises the prospect of exponential increases in AEs.

Deloitte's Cognitive AE Intake and Processing offers a better way. This module of the ConvergeHEALTH Safety platform automates intake and processing to help significantly improve the efficiency and quality of your AE lifecycle. It will likely free up resources, helping you to investigate anomaly cases, better manage quality, improve your understanding of product safety profiles, prepare to respond to changing regulations, and evaluate new opportunities for safety insights.

Shift from low-value tasks to high-impact insights

Don't settle for incremental change. This innovative cognitive- and automation-driven application can transform your AE process and unlock new opportunities to improve your understanding of drug risk profiles.

Here's how it works. Our cognitive engine— with machine learning, natural language processing and generation, plus robotic automation capabilities—is specifically designed to power case entity extraction and coding while also delivering quality improvement recommendations. Workflow automation eliminates manual processes from case receipt through medical and quality review to help improve quality, compliance, and richness of case data available for scientific safety analysis downstream.

This means that safety analysts can shift their focus from low-value manual processes to understanding and interpreting insights to enhance product safety and improve patient outcomes.
Deloitte’s leading life sciences practice can deliver the experience, knowledge, and technologies needed to help you effectively navigate the rapidly evolving world of drug safety. If you’re looking for professionals who understand today’s PV issues and deliver innovative solutions, let’s talk.

Glenn Carroll
Principal
Deloitte Consulting LLP
gcarroll@deloitte.com

John Whitebrook
Managing Director
Deloitte Consulting LLP
jowhitebrook@deloitte.com

Aditya Kudumala
Principal
Deloitte Consulting LLP
akudumala@deloitte.com

Should we talk?

There’s more to ConvergeHEALTH Safety

The ConvergeHEALTH Safety platform enables an end-to-end, integrated, and evidence-based model for safety intelligence to help mitigate risk, reduce cost, and improve patient outcomes. The platform architecture supports four modular applications, which can be deployed separately or in combination.

- Cognitive AE Intake and Processing
- Aggregate Reporting and Safety Analysis
- Safety Operations and Compliance
- Signal Detection, Evaluation, and Management

For more information visit www.deloitte.com/us/convergehealth.html